247 related articles for article (PubMed ID: 24692682)
1. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
Smolle E; Taucher V; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
Kobold S; Hegewisch-Becker S; Oechsle K; Jordan K; Bokemeyer C; Atanackovic D
Oncologist; 2009 Dec; 14(12):1242-51. PubMed ID: 20008305
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Colombo N; Mangili G; Mammoliti S; Kalling M; Tholander B; Sternas L; Buzenet G; Chamberlain D
Gynecol Oncol; 2012 Apr; 125(1):42-7. PubMed ID: 22112608
[TBL] [Abstract][Full Text] [Related]
5. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
6. Current and future options in the treatment of malignant ascites in ovarian cancer.
Woopen H; Sehouli J
Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
8. Prolonged response to aflibercept in ovarian cancer relapse: a case report.
Redondo A; Castelo B; Pinto A; Zamora P; Espinosa E
Tumori; 2015 Mar; 101(1):e29-31. PubMed ID: 25702661
[TBL] [Abstract][Full Text] [Related]
9. Normalization of the ovarian cancer microenvironment by SPARC.
Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
12. [The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports].
Kinoshita J; Fushida S; Makino I; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Ninomiya I; Kitagawa H; Tani T; Miyamoto M; Fujimura T; Ota T
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2360-2. PubMed ID: 22202382
[TBL] [Abstract][Full Text] [Related]
13. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
Luo JC; Toyoda M; Shibuya M
Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
Taguchi E; Nakamura K; Miura T; Shibuya M; Isoe T
Cancer Sci; 2008 Mar; 99(3):623-30. PubMed ID: 18201272
[TBL] [Abstract][Full Text] [Related]
16. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
18. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
[TBL] [Abstract][Full Text] [Related]
19. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA; Heiss MM
Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
[TBL] [Abstract][Full Text] [Related]
20. Adult granulosa cell tumor presenting as metastases to the pleural and peritoneal cavity.
Gupta N; Rajwanshi A; Dey P; Suri V
Diagn Cytopathol; 2012 Oct; 40(10):912-5. PubMed ID: 21618710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
